Scalper1 News
Valeant Pharmaceuticals International (VRX) beat analysts’ Q4 estimates and affirmed its guidance Thursday morning, sending shares up 1.5% in the stock market today and to an all-time high. Valeant said cash EPS totaled $2.15, up 76% from the year-earlier quarter and 9 cents above the consensus of analysts polled by Thomson Reuters. Sales rose 109% to $2.06 billion, in line. For the full year, earnings rose 51% to $6.24 a share, with sales up 66% Scalper1 News
Scalper1 News